Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 17, 2020
Daily News
August 17, 2020
- Kaken’s Axillary Hyperhidrosis Drug, JT’s HIF-PH Inhibitor Up for MHLW Panel Review on Aug. 27
August 17, 2020
- COVID-19’s Impact on Pharma Becoming Clearer with New Data, Earnings
August 17, 2020
- Solasia Gets Japan Rights to Isofol’s Cancer Drug
August 17, 2020
- Nippon Shinyaku’s DMD Treatment Approved in US
August 17, 2020
- AbbVie Japan Alters Company Rules for Same-Sex, Common-Law Marriages
August 17, 2020
- MHLW Urges Trade Groups to Ensure Stable Supply of Povidone-Iodine Products
August 17, 2020
- Generic APIs at Crossroads - 4: Professor Calls for Monitoring Drugs Liable to Be in Short Supply, Drawing Up Lists of Substitutes
August 17, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…